BCIQ Profiles

Company Profile ReportTarget Profile Report

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with

Read the full 276 word article

How to gain access

Continue reading with a
two-week free trial.